Journal article
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial
- Abstract:
-
Background: Despite inhaled corticosteroid plus long-acting β2-agonist (ICS/LABA) therapy, 30–50% of patients with moderate or severe asthma remain inadequately controlled. We investigated the safety and efficacy of single-inhaler fluticasone furoate plus umeclidinium plus vilanterol (FF/UMEC/VI) compared with FF/VI.
Methods: In this double-blind, randomised, parallel-group, phase 3A study (Clinical Study in Asthma Pa...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 873.4KB, Terms of use)
-
- Publisher copy:
- 10.1016/s2213-2600(20)30389-1
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet More from this journal
- Volume:
- 9
- Issue:
- 1
- Pages:
- 69-84
- Publication date:
- 2020-09-09
- Acceptance date:
- 2020-08-18
- DOI:
- EISSN:
-
2213-2619
- ISSN:
-
2213-2600
- Pmid:
-
32918892
- Language:
-
English
- Keywords:
- Pubs id:
-
1132562
- Local pid:
-
pubs:1132562
- Deposit date:
-
2021-01-19
Terms of use
- Copyright holder:
- Elsevier Ltd.
- Copyright date:
- 2021
- Rights statement:
- © 2020 Elsevier Ltd. All rights reserved.
- Notes:
-
This is the accepted manuscript version of the article. The final version is available from Elsevier at https://doi.org/10.1016/S2213-2600(20)30389-1
If you are the owner of this record, you can report an update to it here: Report update to this record